Integra LifeSciences Holdings (IART)
Return on total capital
| Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 | ||
|---|---|---|---|---|---|---|
| Earnings before interest and tax (EBIT) | US$ in thousands | 132,446 | 263,488 | 265,072 | 165,101 | 114,061 |
| Long-term debt | US$ in thousands | 1,395,820 | 1,300,490 | 1,388,680 | 1,408,220 | 1,198,560 |
| Total stockholders’ equity | US$ in thousands | 1,587,880 | 1,804,400 | 1,684,800 | 1,514,870 | 1,416,740 |
| Return on total capital | 4.44% | 8.49% | 8.62% | 5.65% | 4.36% |
December 31, 2023 calculation
Return on total capital = EBIT ÷ (Long-term debt + Total stockholders’ equity)
= $132,446K ÷ ($1,395,820K + $1,587,880K)
= 4.44%
Integra Lifesciences Holdings Corp's return on total capital has shown some fluctuation over the past five years. In 2023, the return on total capital was 3.61%, a decrease from the previous year's 7.36%. This decline indicates a decrease in the company's ability to generate profits from its total capital employed.
Comparing 2023 to 2021, the return on total capital increased from 6.10% to 3.61%, showing a mixed trend in profitability. However, the returns in 2023 and 2021 were lower than the returns in 2020 (4.93%) and 2019 (5.74%), indicating a potential decline in the company's overall profitability over the past few years.
Overall, the fluctuating trend in Integra Lifesciences Holdings Corp's return on total capital suggests variability in the company's efficiency in generating returns on the total capital utilized in its operations. Further analysis of the company's financial performance and capital structure may be needed to understand the factors contributing to these changes in profitability.
Peer comparison
Dec 31, 2023